(A) Snapshot from MD of GMP and SCP. (B) Representative brightfield images for cell migration of M2 BMDMs treated with rCHI3L1 (0.6 μg/mL) with or without GMP or SCP at a concentration of 30 μM in the scratch-wound healing assay. (C) Cell migration was assessed by quantifying the occupied area of migrated cells. Data are presented as mean ± SD from at least 3 independent experiments. P values were calculated using 1-way ANOVA with Tukey’s multiple comparisons test. ***P < 0.001; ****P < 0.0001. (D) IB analysis of protein-binding complexes using co-IP with Gal3 antibody in THP-1 cells treated with SCP or GMP (20 μM for 24 hours). (E) Representative MRI from mice after intracranial injection of GL261-CHI3L1 cells after the treatment of SCP and GMP, respectively. Tumor volume was measured by T2 sequences for infiltrative tumors in the mouse brain (yellow line). (F) Kaplan-Meier tumor-free survival analysis of mice bearing GL261-CHI3L1 tumors treated with indicated peptides. Frequency of M1/M2-like MDMs (G) and CD8⁺ T cells with expression of PD-1 and CTLA-4 (H) in tumors derived from syngeneic mice bearing GL261-CHI3L1 under treatment with GMP versus SCP. Each dot represents 1 mouse; data are presented as the mean ± SEM. P values were calculated using a 1-tailed, unpaired t test.